VFC Resolution Update: Influenza Vaccines

Frank Whitlatch
Immunization Services Division
National Center for Immunization and Respiratory Diseases
June 27, 2019
Note

- **Yellow font/highlight** in the presentation is used to indicate changes to the resolution in comparison to the prior approved version.
Purpose of the Resolution

- The purpose of this resolution is to update the table of inactivated influenza vaccines in the VFC program.
A. Inactivated Influenza Vaccine

Eligible Groups

All children aged 6 months through 18 years.

Recommended Vaccination Schedule

- 6 months through 8 years: 1 or 2 doses, as noted in the current ACIP recommendations
- 9 through 18 years: 1 dose
## A. Inactivated Influenza Vaccine

The table below lists the currently approved inactivated influenza vaccines in the VFC program, including the age indications for each vaccine.

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Presentation</th>
<th>Age Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afluria (Quadrivalent)</td>
<td>0.25mL pre-filled syringe</td>
<td>6 through 35 months</td>
</tr>
<tr>
<td>Afluria (Quadrivalent)</td>
<td>0.5 mL pre-filled syringe</td>
<td>&gt;= 36 months</td>
</tr>
<tr>
<td>Afluria (Quadrivalent)</td>
<td>5.0mL multi-dose vial</td>
<td>&gt;= 6 months</td>
</tr>
<tr>
<td>Fluarix (Quadrivalent)</td>
<td>0.5 mL pre-filled syringe</td>
<td>&gt;= 6 months</td>
</tr>
<tr>
<td>Flucelvax (Quadrivalent)</td>
<td>0.5 mL pre-filled syringe</td>
<td>&gt;= 4 years</td>
</tr>
<tr>
<td>Flucelvax (Quadrivalent)</td>
<td>5.0mL multi-dose vial</td>
<td>&gt;= 4 years</td>
</tr>
<tr>
<td>Flulaval (Quadrivalent)</td>
<td>0.5 mL pre-filled syringe</td>
<td>&gt;= 6 months</td>
</tr>
<tr>
<td>Flulaval (Quadrivalent)</td>
<td>5.0 mL multi-dose vial</td>
<td>&gt;= 6 months</td>
</tr>
<tr>
<td>Fluzone (Quadrivalent)</td>
<td>0.25mL pre-filled syringe</td>
<td>&gt;= 6 through 35 months</td>
</tr>
<tr>
<td>Fluzone (Quadrivalent)</td>
<td>0.5mL prefilled syringe/single-dose vial</td>
<td>&gt;= 6 months</td>
</tr>
<tr>
<td>Fluzone (Quadrivalent)</td>
<td>5.0mL multi-dose vial</td>
<td>&gt;= 6 months</td>
</tr>
</tbody>
</table>

Note: The use of brand names is not meant to preclude the use of other comparable licensed vaccines.
A. Inactivated Influenza Vaccine

**Recommended Intervals/Recommended Dosage**

**Recommended Intervals**
- Minimum Age: 6 months
- Minimum interval between dose 1 and dose 2 (where applicable): 4 weeks

**Recommended Dosage**
- Refer to product package insert.
A. Inactivated Influenza Vaccine

Contraindications and Precautions

Contraindications:

- History of severe allergic reaction to any component of the vaccine or after previous dose of any influenza vaccine. However, ACIP makes specific recommendations for the use of influenza vaccine in persons with egg allergy (see Influenza Vaccination of Persons with a History of Egg Allergy, in https://www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm).

Precautions:

- Moderate or severe acute illness with or without fever
- GBS within 6 weeks following a previous dose of influenza vaccine
B. Live Attenuated Influenza Vaccine

Eligible Groups

All healthy, non-pregnant children and adolescents (i.e., those who do not have an underlying medical condition that predisposes them to influenza complications) aged 2 through 18 years.

Recommended Vaccination Schedule

- 2 through 8 years: 1 or 2 doses, as noted in the current ACIP recommendations
- 9 through 18 years: 1 dose
B. Live Attenuated Influenza Vaccine

Recommended Intervals/Recommended Dosage

Recommended Intervals

- Minimum Age: 2 years
- Minimum interval between dose 1 and dose 2 (where applicable): 4 weeks

Recommended Dosage

- Refer to product package insert.
B. Live Attenuated Influenza Vaccine

Contraindications and Precautions

Contraindications and precautions can be found at:
https://www.cdc.gov/mmwr/volumes/66/rr/rr6602a1.htm
Statement Regarding Update Based on Published Documents

- If an ACIP recommendation regarding influenza vaccination is published within 6 months following this resolution, the relevant language above (except in the eligible groups sections) will be replaced with the language in the recommendation and incorporated by reference to the URL.